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Acute kidney injury (AKI) is a common condition with
significant associated morbidity and mortality. The
insensitivity and non-specificity of traditional markers of
renal dysfunction prevent timely diagnosis, estimation of the
severity of renal injury, and the administration of possible
therapeutic agents. Here, we determine the prognostic ability
of urinary liver-type fatty acid-binding protein (L-FABP), and
further characterize its sensitivity and specificity as a
biomarker of AKI. Initial western blot studies found increased
urinary L-FABP in patients with confirmed AKI. A more
extensive cross-sectional study found significant increases in
urinary L-FABP, normalized to urinary creatinine, in 92
patients with established AKI compared with 62 patients
without clinical evidence of AKI. In hospitalized patients, the
diagnostic performance of urinary L-FABP for AKI, assessed
by the area under the receiver operating characteristic
curve, was 0.93. This compares favorably with other
established biomarkers of AKI such as kidney injury
molecule-1, neutrophil gelatinase-associated lipocalin,
N-acetyl-b-glucosaminidase, and interleukin-18. Our study
shows that age-adjusted urinary L-FABP levels were
significantly higher in patients with poor outcome, defined
as the requirement for renal replacement therapy or the
composite end point of death or renal replacement therapy.
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Acute kidney injury (AKI) is a common medical condition
with significant associated morbidity and mortality. In
adults, AKI has been reported to complicate 1–7%1–6 of all
hospital admissions and 1–25%7,8 of intensive care unit
(ICU) admissions. Despite impressive progress in the
understanding of the molecular and biochemical mechanisms
of AKI, as well as in the general care of patients affected,
mortality rates in the ICU setting remain between 50–70%,9
with a significant number of survivors exhibiting persistent
evidence of renal dysfunction.4,10 Unfortunately, notable
improvements in the therapeutics of AKI have been few since
the introduction of renal replacement therapy into clinical
practice more than 50 years ago.
Over the past 10 years, increased attention has been
focused on identifying and addressing impediments to
progress in AKI research. One problem area widely
recognized is the continued reliance on markers for the
diagnosis of AKI that do not reflect actual injury to renal
cells, but rather the functional consequences of injury. In
current practice, AKI is identified by increases in serum
creatinine (SCr) measurements over time. It is well
established, however, that SCr is a suboptimal marker that
follows renal injury, when levels are often not reflective
of the glomerular filtration rate (GFR) because of a number
of renal and non-renal influences. In the setting of AKI,
the dynamic relationship between SCr and GFR inhibits
the ability to accurately estimate the timing of injury
and the severity of dysfunction after injury. As dictated by
the laws of mass balance, a sudden fall in GFR to a constant
low level causes a gradual increase in SCr until a new
steady state between generation and excretion is achieved.
Thus, the rate of SCr increase after AKI is dependent
on many factors, including the new GFR, rate of generation,
rate of tubular secretion, and volume of distribution.
As a result, severe injury and large changes in GFR may be
associated with small, gradual changes in SCr during the
first 48 h after injury, resulting in delayed diagnosis,
underestimation of the degree of injury, and delayed
intervention.
Intensive investigative efforts have led to the identification
of a number of urinary proteins, including kidney
injury molecule-1 (KIM-1), neutrophil gelatinase-associated
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lipocalin (NGAL), and interleukin-18 (IL-18), which have
emerged as markers of AKI. It is anticipated that further
characterization and validation of individual biomarkers
and/or biomarker panels will enable earlier diagnosis,
patient stratification into groups at varying risks of develop-
ing AKI, and targeted intervention after the diagnosis of AKI
has been made, ultimately resulting in improved patient
outcomes.
The fatty acid-binding proteins (FABPs) are small
cytoplasmic proteins abundantly expressed in tissues with
active fatty acid metabolism. Nine distinct types have been
identified, with each named after the tissue in which they
were first identified.11 The primary function of FABPs
seems to be the facilitation of long-chain fatty acid transport
from the plasma membrane to sites for b-oxidation.11 In
addition, FABPs may also have a role in the reduction of
cellular oxidative stress, binding fatty acid oxidation
products, and limiting the toxic effects of oxidative
intermediates on cellular membranes.12,13 The putative
antioxidant properties of FABPs have stimulated interest
in these proteins as potential tissue-specific markers of
injury.
Liver-type FABP (L-FABP) was initially identified in
hepatocytes and later found to be expressed in the human
renal proximal tubule epithelium,11 a nephron segment
largely dependent on energy derived from fatty acid
metabolism for normal cellular transport processes. In
preclinical studies, renal L-FABP expression protected against
tubulointerstitial damage in models of proximal tubule
protein overload, as well as against unilateral ureteral
obstruction.14,15 Clinical studies have established L-FABP as
a promising biomarker in both chronic kidney disease16–18
and AKI.19–21 In addition, Nakamura et al.22 recently reported
urinary L-FABP levels to be significantly elevated in patients
with septic shock and concluded that this was likely a
reflection of associated renal tubular injury. They also noted
that urinary L-FABP levels were not correlated with the need
for dialysis; however, predictive ability for other outcome
measures was not reported.
To further establish the utility of urinary L-FABP as a
biomarker of AKI, we conducted a cross-sectional study
comparing urinary L-FABP excretion in a heterogeneous
group of adult patients with established AKI (n¼ 92) with
hospitalized and ambulatory control subjects without clinical
evidence of kidney injury (n¼ 68). Cross-sectional studies
provide important information on kidney biomarker
research. They eliminate the inherent uncertainty associated
with prospective short-term studies—uncertainty due to the
fact that in the absence of a kidney biopsy there is no current
gold standard for the diagnosis of AKI, especially injury that
is not associated with an increase in SCr. All of the cases in
the study defined as AKI were associated with clinical
confirmation, as well as with increases in SCr. Our results
indicate that urinary L-FABP is a highly sensitive and specific
marker for the diagnosis and prognosis of established AKI of
varying etiology.
RESULTS
Urinary L-FABP detection by western blot analysis
Western blot analysis (Figure 1) was performed on urine
samples from six patients with known AKI (secondary to
sepsis and aminoglycoside toxicity), one healthy control, and
one ICU control patient who did not have clinical evidence of
AKI using conventional metrics. L-FABP pure protein was
included as a reference standard. Urinary L-FABP was
undetectable in healthy control urine and low levels were
observed in the urine of some patients in the critically ill
control group. In sharp contrast, all patients with established
AKI had easily detectable levels of urinary L-FABP.
Cross-sectional study of urinary L-FABP in patients with
established AKI
A total of 92 patients with established AKI and 68 control
subjects were studied. To obtain a diverse control group,
healthy volunteers (n¼ 29), critically ill patients without a
diagnosis of AKI (n¼ 13), and patients who were scheduled
for elective cardiac catheterization without clinical evidence
of AKI (n¼ 26) were recruited. These subjects are a large
subgroup of those investigated in our recent study showing
the comparative value of multiple biomarkers in the
diagnosis and prognosis of AKI.23 Clinical characteristics
are presented in Table 1.
Median urinary L-FABP levels normalized to urinary
creatinine were significantly higher in patients with AKI than
in control subjects, whether analyzed as individual groups
(healthy volunteers versus AKI, ICU control versus AKI, or
precatheterization versus AKI) or together (all controls versus
AKI). Scatterplots of urinary L-FABP levels (log scale) and
summary statistics are shown in Figure 2.
Diagnostic ability of urinary L-FABP. Diagnostic perfor-
mance was assessed by comparing normalized urinary
L-FABP levels in patients with AKI versus control subjects
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Figure 1 |Western blot analysis of urine from patients with
and without established acute kidney injury (AKI). The first
lane was loaded with liver-type fatty acid-binding protein (L-FABP)
as a reference standard. Remaining lanes were loaded with urine
from patients with AKI in the setting of sepsis or aminoglycoside
administration, a critically ill (intensive care unit (ICU)) patient
without clinical evidence of AKI, and a healthy volunteer. Western
blot analysis was carried out with a polyclonal antibody to human
L-FABP.
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using receiver operating characteristic area under the curves
(ROC-AUC). Figure 3 shows the ROC curve for AKI versus
all hospitalized control subjects (ICU controls and precathe-
terization controls; AUC-ROC¼ 0.93). Table 2 summarizes
the ROC-AUC, sensitivity, specificity, and cutoff values for
AKI versus control patients, analyzed together and as
individual groups. Urinary L-FABP effectively distinguished
control patients from those with AKI (ROC-AUC¼ 0.96),
distinguished precatheterization controls from those with
AKI (ROC-AUC¼ 0.98), and allowed perfect discrimination
between healthy volunteers and those with AKI (AUC¼ 1.0).
Diagnostic performance remained high when ICU controls
were analyzed alone against those with AKI (AUC¼ 0.82).
To determine the diagnostic ability of urinary L-FABP
relative to other established biomarkers of AKI, ROC-AUCs
were calculated for AKI versus hospitalized controls for
urinary NGAL, KIM-1, N-acetyl-b-glucosaminidase (NAG),
and IL-18. These results are summarized in Table 3. Urinary
L-FABP performed at a level comparable to that of NGAL,
NAG, and KIM-1, and exceeded that of IL-18. Pairwise
comparisons revealed no significant difference between the
AUC-ROCs for L-FABP versus NGAL, KIM-1, and NAG.
There was a significant difference between the AUC-ROCs for
L-FABP and IL-18 (P¼ 0.005).
Prognostic ability of urinary L-FABP. Patients with AKI had
an in-hospital mortality rate of 36 and 43% required renal
replacement therapy (RRT); 59% reached the composite
outcome of death or RRT. In age-adjusted analysis using log-
transformed, normalized values, urinary L-FABP emerged as
a significant predictor of RRT (P¼ 0.02) and of the
composite end point of death/RRT (P¼ 0.03); urinary
L-FABP did not predict in-hospital mortality (P¼ 0.26).
Normalized urinary L-FABP levels of subjects reaching the
combined end point of death/RRT and of those who did not
are shown in box and whisker plots in Figure 4. Age-adjusted
Table 1 | Subject characteristics
Healthy
volunteers
(n=26)
Precatheterization
controls
(n=29)
ICU
controls
(n=13)
All
controls
(n=68)
AKI
(n=92)
Age (±s.d.) 34.7
(±9.1)
67.0
(±14.5)
67.6
(±13.1)
54.8
(±20.1)
60.5
(±17.2)
Gender
Male (%) 27 69 69 54 57
Ethnicity
Black (%) 12 7 0 9 11
Cause of AKIa
ATN (%) 30
Sepsis (%) 33
Nephrotoxins (%) 7
Contrast (%) 5
Other (%) 25
Reason for ICU admission
Post-surgery (%) 54
Trauma (%) 32
Sepsis (%) 14
Abbreviations: AKI, acute kidney injury; ATN, acute tubular necrosis; ICU, intensive
care unit.
aA single most likely cause of AKI was determined based on chart review.
*P <0.0001
**P =0.0002
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Figure 2 |Cross-sectional data. Comparison of urinary liver-type
fatty acid-binding protein (L-FABP) in acute kidney injury (AKI) and
control patients. Scatterplot of all urine L-FABP measurements by
ELISA. Urinary L-FABP levels were significantly elevated in patients
with AKI (median 236; interquartile range (IQR) 74–610) when
compared with healthy controls (median 1.59; IQR 0.89–3.05;
Po0.0001, Mann–Whitney U-Test), precatheterization controls
(Precath, median 6.48; IQR 2.78–10.86; Po0.0001), intensive care
unit (ICU) controls (median 41.48; IQR 18.25–83.61; P¼ 0.0002),
and all controls together (median 3.86; IQR 1.57–11.32; Po0.0001).
Cr, creatinine.
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Figure 3 |Diagnostic performance of urinary liver-type fatty
acid-binding protein (L-FABP) for the identification of
established acute kidney injury (AKI) in hospitalized patients.
Receiver operating characteristic curve for AKI versus hospitalized
controls (intensive care unit controls and precatheterization
controls). Area under the curve (AUC) was 0.93 (95% CI 0.88–0.97)
using a cutoff of 47.1 ng per mg Cr; sensitivity was 83% (95% CI
73–90%), and specificity was 90% (95% CI 77–97%). CI, confidence
intervals; Cr, creatinine.
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SCr levels at the time of urine collection were not
significantly associated with mortality and/or RRT.
Urinary L-FABP in AKI of different causes. A single diagnosis
was established for each patient with AKI on the basis of
chart review (acute tubular necrosis (ischemia, post-cardiac
surgery, pigment nephropathy) (n¼ 28); sepsis (n¼ 30);
nephrotoxin exposure (n¼ 6); contrast nephropathy (n¼ 5);
others (obstruction, acute interstitial nephritis, acute glo-
merulonephritis, multiple myeloma, prerenal, vaso-occlusive
disease, tumor lysis syndrome) (n¼ 23). No statistical dif-
ference in urinary L-FABP levels among diagnostic cate-
gories was observed (Kruskal–Wallis; P¼ 0.15). In general,
a trend toward higher levels was observed in acute tubular
necrosis and sepsis, and lower levels in contrast nephro-
pathy. Normalized urinary L-FABP levels for each dia-
gnostic category are shown in box and whisker plots in
Figure 5.
DISCUSSION
Over the past several decades, numerous advances have been
made in the understanding of the pathophysiological
mechanisms implicated in AKI24,25 and the compensatory
Table 2 | Diagnostic performance characteristics of urinary L-FABP for the identification of established AKI
AUC-ROC (95% CI) Cutoff (ng per mg Cr) Sensitivity (95% CI) Specificity (95% CI)
AKI versus hospitalized controlsa 0.93 (0.88–0.97) 47.1 83% (73–90%) 90% (77–97%)
AKI versus all controls 0.96 (0.92–0.98) 26.1 95% (88–98%) 84% (73–92%)
AKI versus healthy volunteers 1.00 (0.97–1.00) 8.1 100% (96–100%) 100% (87–100%)
AKI versus precath. controls 0.98 (0.94–1.00) 32.5 92% (85–97%) 93% (77–99%)
AKI versus ICU controls 0.82 (0.74–0.89) 99.0 70% (59–79%) 85% (55–98%)
Abbreviations: AKI, acute kidney injury; AUC-ROC, area under the receiver operating characteristic curves; CI, confidence interval; Cr, creatinine; ICU, intensive care unit;
L-FABP, liver-type fatty acid-binding protein; Precath, precatheterization.
aHospitalized controls¼ ICU controlsþprecatheterization controls.
Table 3 | Comparative diagnostic performance of urinary L-FABP, NGAL, KIM-1, NAG, and IL-18 for the identification of
established AKI in hospitalized patients
Biomarker AUC-ROC (95% CI) Cutoff Sensitivity (95% CI) Specificity (95% CI)
L-FABP (ng per mg Cr) 0.93 (0.88–0.97) 47.1 83% (73–90%) 90% (77–97%)
NGAL (ng per mg Cr) 0.92 (0.86–0.96) 186.8 81% (71–89%) 100% (92–100%)
KIM-1 (ng per mg Cr) 0.89 (0.82–0.94) 1.7 77% (67–85%) 100% (92–100%)
NAG (U per mg Cr) 0.89 (0.82–0.94) 0.007 99% (94–100%) 64% (48–78%))
IL-18 (pg per mg Cr) 0.83* (0.76–0.89) 2.2 71% (60–80%) 90% (77–93%)
Abbreviations: AKI, acute kidney injury; AUC-ROC, area under the receiver operating characteristic curve; CI, confidence interval; Cr, creatinine; IL, interleukin; KIM, kidney
injury molecule; L-FABP, liver-type fatty acid-binding protein; NAG, N-acetyl-b-glucosaminidase; NGAL, neutrophil gelatinase-associated lipocalin.
*P=0.005 compared with L-FABP.
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Figure 4 |Comparison of urinary liver-type fatty acid-binding
protein (L-FABP) levels in patients with established acute
kidney injury (AKI) by clinical outcome. Box and whisker plots
of normalized urinary L-FABP levels in patients meeting the
composite end point of death/renal replacement therapy (RRT)
and those who survived without RRT. Cr, creatinine.
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Figure 5 |Comparison of urinary liver-type fatty acid-binding
protein (L-FABP) levels in patients with acute kidney injury
(AKI) by cause. Box and whisker plots of normalized urinary
L-FABP levels in patients with established AKI caused by acute
tubular necrosis (ATN), sepsis, nephrotoxin exposure, contrast-
induced nephropathy, and other underlying disease.
Cr, creatinine.
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mechanisms involved in renal 5recovery. 26,27 In addition,
important advances have been made in the treatment of
patients with AKI, both in terms of dialytic therapy and
supportive ICU care.28–31 Unfortunately, commensurate
improvements in patient outcomes have not been observed.
Reliance on SCr as a marker of renal injury has contributed
to the slow translation of basic science discovery to
therapeutically effective approaches in clinical practice.
Recent efforts have led to the identification and char-
acterization of a number of promising biomarkers of AKI,
including KIM-1,32–36 NGAL,37–39 and IL-18.40,41 Urinary
L-FABP has been studied clinically in a variety of renal
pathophysiologic states14,42,43 and has been shown to hold
promise in the monitoring of progressive diabetic and non-
diabetic chronic kidney disease.17 Recent reports have
established urinary L-FABP as a useful biomarker in clinical
models of ischemic AKI. Yamamoto et al.21 reported that
urinary L-FABP levels correlated well with the ischemic time
of the transplanted kidney and with the length of hospital
stay in human living related-donor renal transplant
recipients. More recently, Portilla et al.20 investigated urinary
L-FABP as a biomarker of AKI in pediatric patients after
cardiac surgery and found that levels at the 4 h post-operative
time point were predictive of those who subsequently
developed AKI with an ROC-AUC of 0.810 (sensitivity
0.714; specificity 0.684). In addition, Nakamura et al.19
reported that baseline urinary L-FABP levels were signifi-
cantly higher in those patients who developed contrast
nephropathy after coronary angiography; however, the
authors did not evaluate the diagnostic performance of
urinary L-FABP in predicting AKI. Our study evaluated a
heterogeneous group of adult patients and showed signifi-
cantly elevated urinary L-FABP levels in established AKI of
varying etiology, including acute tubular necrosis, sepsis, and
nephrotoxin exposure. Our results suggest that urinary
L-FABP has broad utility in the diagnosis of AKI; however,
further evaluation is necessary to establish the temporal
pattern of excretion in the various forms of AKI, as urine
specimens in our study were obtained after the diagnosis of
AKI was made.
The study population for this investigation represented a
large subset of the subjects described in our recent study
showing the comparative value of multiple biomarkers in the
diagnosis and prognosis of AKI.23 The diagnostic ability of
urinary L-FABP (ROC-AUC¼ 0.93) in hospitalized patients
was very good, comparable to other well-described biomar-
kers of AKI, including NGAL (0.92), KIM-1 (0.89), NAG
(0.89), and statistically better than IL-18 (0.83). As expected,
urinary L-FABP diagnostic performance characteristics were
optimal when AKI was compared with healthy volunteers
(ROC-AUC¼ 1.00). Although diagnostic performance re-
mained high when AKI patients were compared against
hospitalized patients without a diagnosis of AKI, consider-
able overlap of urinary L-FABP values was noted, particularly
among AKI patients and ICU controls. There are at least two
explanations for this phenomenon. It is possible that
increased urinary L-FABP levels in acutely ill ICU patients
without a diagnosis of AKI are indicative of some other
systemic process and therefore reflect decreased specificity
for AKI. Alternatively, it is possible that increased urinary
L-FABP levels in this setting are due to subtle renal injury
that does not result in increased SCr and therefore reflect
increased sensitivity for AKI. The difficulty in differ-entiating
between these two possibilities will persist as long as new
biomarker data are evaluated against a suboptimal reference
standard (SCr). It is also interesting that a number of patients
who were not identified clinically as having renal disease had
elevated urinary L-FABP levels before cardiac catheterization.
This suggests that urinary L-FABP may prove to be useful for
a more sensitive screening of patients for renal disease when
their SCr is within the normal range.
This study did not include blood collections for serum
biomarker quantification. As a result, it is not possible to
correlate serum and urinary L-FABP levels in this cohort.
However, previous studies in patients with chronic kidney
disease and sepsis have shown that serum L-FABP levels do
not have an influence on urinary levels and that urinary
L-FABP levels in patients with liver disease are not
significantly higher than those in healthy subjects.17,22
Therefore, in our patients with established AKI, urinary
excretion of L-FABP is very likely to reflect a renal and not a
hepatic source. To confirm that liver-derived L-FABP does
not contribute to urinary levels, particularly in the setting of
sepsis and/or shock, future studies should include determi-
nation of serum L-FABP levels and liver function tests.
This is the first study to establish urinary L-FABP levels as
a predictor of adverse outcome (RRT, death/RRT) in patients
with established AKI. Thus, urinary L-FABP may be added to
the growing list of biomarkers that promise to aid in
prognosis in the setting of AKI. This is notable given that
improved AKI prognostic paradigms are critical for appro-
priate stratification strategies in future studies in the
evaluation of novel AKI therapies.
Given the inherent renal heterogeneity and the disparate
settings under which kidney injury occurs, a panel of
carefully selected biomarkers may prove to be most
appropriate in the diagnosis and prognosis of AKI. Develo-
pment of such a panel will require large, well-designed
prospective studies comparing multiple biomarkers in the
same set of urine samples over extended time courses. Such
studies will allow temporal patterns of biomarker elevation to
be established, patterns that may be specific to the
mechanism of injury (nephrotoxicant, ischemia, sepsis,
allograft rejection, etc.), population of interest (elderly,
pediatric, etc.), and/or co-occurring disease states (diabetes,
heart disease, sepsis, etc.). Although these prospective studies
are crucial, they are not without their own limitations for
biomarker validation. Ambiguity of results will persist as long
as biomarkers are compared against SCr. For example, a very
sensitive biomarker may be increased in mild kidney injury in
which SCr remains unchanged. Alternatively, a very specific
biomarker may not be increased in a setting in which an
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increase in SCr is related to functional changes and
not kidney tubular injury. This cross-sectional study, in
which the diagnosis of AKI is firm, is less susceptible to these
ambiguities.
In conclusion, urinary L-FABP is a sensitive and specific
marker of AKI in patients. Higher levels predict the need for
RRT and the composite end point of death/RRT in patients
with AKI. Therefore, urinary L-FABP should be included in
future studies evaluating the diagnostic and prognostic
significance of urinary biomarker levels in AKI.
MATERIALS AND METHODS
Patient selection for urine collection
Human subjects were recruited from the inpatient nephrology
consultation service (established AKI), inpatient cardiology service
(precatheterization controls), critical care service (ICU controls),
and hospital employees (healthy volunteers) of Brigham and
Women’s Hospital. The institutional review board approved the
protocols for subject recruitment and specimen collection. Patients
with established AKI hadX50% increase in SCr from admission or
known baseline values. Causes of AKI were diverse, including acute
tubular necrosis, sepsis, and nephrotoxin exposure (Table 1).
Healthy volunteers were excluded if they reported a recent
hospitalization, diagnosis of chronic kidney disease, or treatment
with nephrotoxic medications (non-steroidal anti-inflammatory
drugs were allowed). Patients undergoing cardiac catheterization
and those admitted to the ICU were included in the non-AKI cohort
if they had a normal urine output, stable SCr during hospitalization,
and an estimated GFR 450ml/min using the Modification of Diet
in Renal Disease equation.
ELISA for urinary L-FABP quantification
Urine samples were prepared as described above. All samples were
assayed in duplicate using a commercially available sandwich ELISA
kit (HK404, Hycult Biotechnology, Uden, The Netherlands).
Urinary L-FABP levels were normalized to urinary creatinine, which
was measured with Beckman Creatinine Analyzer 2 (Beckman
Coulter, Fullerton, CA, USA).
NGAL, KIM-1, NAG, and IL-18 quantification
Urinary NGAL, KIM-1, and IL-18 levels were quantified using a
microbead-based sandwich ELISA. KIM-1 and NGAL assays were
developed and evaluated as previously described.23 IL-18 assay
materials were commercially available from Bio-Rad (Hercules, CA,
USA). Urinary NAG was measured spectrophotometrically using a
commercially available colorimetric assay (Roche Diagnostics, Basel,
Switzerland).
Urine samples
Urine was collected from spontaneous voids or from indwelling
Foley catheters and subsequently centrifuged to remove cellular
components. The supernatant was aliquoted in 1.8ml eppendorf
tubes and frozen within 2 h of collection at 80 1C. At the time of
assay, samples were thawed, vortexed, and centrifuged at 14,000
RPM at 4 1C for 5min and assays performed in duplicate for
biomarker measurement.
Western blot analysis
Urinary total protein was determined using the BCA Protein Assay
Kit (Thermo Fisher Scientific, Rockford, IL, USA). In an effort to
sensitively detect L-FABP in control urines, equal concentrations of
urine protein were loaded per well and subjected to standard
western blot analysis with affinity-purified goat polyclonal antibody
raised against human L-FABP (AF2964, R&D Systems, Minneapolis,
MN, USA). Standard human L-FABP protein (Hycult Biotechno-
logy) was used as a reference standard.
Statistics
Continuous variables are expressed as means±standard deviation
or medians. Urinary L-FABP levels were compared using the
Mann–Whitney U-Test. Diagnostic performance was assessed using
the ROC curve. The AUC for a diagnostic test ranges from 0.5 (no
better than chance alone) to 1.0 (perfect test, equivalent to the gold
standard). Comparative diagnostic performance of urinary L-FABP
versus NGAL, KIM-1, NAG, and IL-18 was determined using
pairwise comparison of ROC-AUCs.44 The ability of urinary L-FABP
to predict adverse outcome in established AKI was tested using
logistic regression analysis, adjusting for age. A two-tailed P-value of
o0.05 was considered to be statistically significant. JMP version 7.0
(SAS Institute, Cary, NC, USA) and MedCalc Version 9.5.0
(MedCalc Software, Mariakerke, Belgium) statistical software were
used for analyses.
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